Aligned with this concept, recently a combination of erlotinib and HGF scavenging antibody L2G7 was shown to significantly decrease tumor growth and improve the OS in EGFRvIII/cMET+/HGF+/PTEN−/− glioma models compared to single agents [64]. Here, MET is linked to glioma.